Patents by Inventor Robert H. Getzenberg

Robert H. Getzenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
    Publication number: 20040018973
    Abstract: Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies.
    Type: Application
    Filed: January 24, 2003
    Publication date: January 29, 2004
    Applicant: University of Pittsburgh
    Inventors: Anthony J. Bauer, Gisela Bruenagel, Robert H. Getzenberg, Robert E. Schoen
  • Nuclear matrix proteins, polynucleotide sequences encoding them, and their use
    Publication number: 20030228640
    Abstract: A novel prostate cancer marker is described that is found in cancerous and normal cells of the prostate in individuals that have prostate cancer but is not found in the prostate of individuals without the disease. In addition, it is present in normal tissue adjacent to the tumor tissue in individuals having prostate cancer. It is, however, absent in the prostate of individuals without the disease. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, are also described.
    Type: Application
    Filed: February 28, 2003
    Publication date: December 11, 2003
    Applicant: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Nuclear matrix proteins, polynucleotide sequences encoding them, and their uses
    Publication number: 20030170754
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue, particularly prostate tissue, are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Application
    Filed: July 19, 2002
    Publication date: September 11, 2003
    Applicant: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Nuclear matrix proteins polynucleotide sequences encoding them and their use
    Patent number: 6617432
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue, particularly prostate tissue, are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: September 9, 2003
    Assignee: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Nuclear matrix proteins
    Publication number: 20030143621
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Application
    Filed: January 29, 2003
    Publication date: July 31, 2003
    Applicant: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Donald S. Coffey, Alan W. Partin, Robert H. Getzenberg
  • Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
    Publication number: 20030134280
    Abstract: The present invention is based on the elucidation of the global changes in gene expression in prostate tissue isolated from patients exhibiting different clinical states of prostate hyperplasia as compared to normal prostate tissue as well as the identification of individual genes that are differentially expressed in diseased prostate tissue.
    Type: Application
    Filed: September 24, 2001
    Publication date: July 17, 2003
    Inventors: William E. Munger, Prakash Kulkarni, Robert H. Getzenberg, Iwao Waga, Jun Yamamoto
  • Identifying drugs for and diagnosis of Benign Prostatic Hyperplasia using gene expression profiles
    Publication number: 20030134324
    Abstract: The present invention is based on the elucidation of the global changes in gene expression in prostate tissue isolated from patients exhibiting different clinical states of prostate hyperplasia as compared to normal prostate tissue as well as the identification of individual genes that are differentially expressed in diseased prostate tissue.
    Type: Application
    Filed: June 5, 2001
    Publication date: July 17, 2003
    Inventors: William E. Munger, Prakash Kulkarni, Robert H. Getzenberg, Iwao Waga, Jun Yamamoto
  • NUCLEAR MATRIX PROTEINS
    Publication number: 20020168695
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Application
    Filed: October 20, 1998
    Publication date: November 14, 2002
    Inventors: DONALD S. COFFEY, ALAN W. PARTIN, ROBERT H. GETZENBERG
  • Bladder nuclear matrix proteins, polynucleotide sequences encoding them, and their use
    Publication number: 20020076737
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Application
    Filed: May 30, 2001
    Publication date: June 20, 2002
    Inventor: Robert H. Getzenberg
  • Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
    Publication number: 20010021507
    Abstract: Nuclear matrix proteins (NMP) are useful markers in diagnosing and monitoring the stage of malignancy of a cell, and in treating cell proliferative disorders associated with the NMP.
    Type: Application
    Filed: May 8, 2001
    Publication date: September 13, 2001
    Inventor: Robert H. Getzenberg
  • Antibodies to bladder cancer nuclear matrix proteins and their use
    Patent number: 6280956
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in bladder tissue are provided, which can be used to generate antibodies that differentiate between normal and cancerous bladder tissue. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a bladder cell and treating bladder cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 28, 2001
    Assignee: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use
    Patent number: 6232443
    Abstract: Nuclear matrix proteins (NMP) are useful markers in diagnosing and monitoring the stage of malignancy of a cell, and in treating cell proliferative disorders associated with the NMP.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: May 15, 2001
    Assignee: University of Pittsburgh
    Inventor: Robert H. Getzenberg
  • Nuclear matrix proteins
    Patent number: 6030793
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: February 29, 2000
    Assignee: The John Hopkins University School of Medicine
    Inventors: Donald S. Coffey, Alan W. Partin, Robert H. Getzenberg
  • Antibodies to nuclear matrix proteins
    Patent number: 5874539
    Abstract: Antibodies directed to nuclear matrix proteins (NMP) are provided. Such antibodies are useful markers in diagnosing and monitoring the stage of malignancy of a cell.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 23, 1999
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Donald S. Coffey, Alan W. Partin, Robert H. Getzenberg
  • Bladder nuclear matrix proteins, polynucleotide sequences encoding them, and their use
    Patent number: 5866535
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: February 2, 1999
    Assignee: University of Pittsburgh
    Inventors: Robert H. Getzenberg, Robert H. Bahnson
  • Nuclear matrix proteins
    Patent number: 5849509
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Donald S. Coffey, Alan W. Partin, Robert H. Getzenberg
  • Method for detecting prostate cancer using a reagent which binds prostate cancer-1 protein
    Patent number: 5824490
    Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. Also provided is an in vitro method for detecting prostate cancer in a sample employing a reagent that reacts with the NMP designated PC-1 (prostate cancer-1).
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 20, 1998
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Donald S. Coffey, Alan W. Partin, Robert H. Getzenberg